<DOC>
	<DOCNO>NCT00161707</DOCNO>
	<brief_summary>The purpose randomize , double-blind , placebo-controlled study evaluate short-term safety inhale recombinant alpha 1-antitrypsin ( rAAT ) subject alpha 1-antitrypsin deficiency . The subject randomize receive placebo one 4 dos rAAT . The 4 dos test consecutive manner low high .</brief_summary>
	<brief_title>Safety Study Aerosolized , Recombinant Alpha 1-Antitrypsin Subjects With Alpha 1-Antitrypsin Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Male female 18 year age older Endogenous plasma AAT level &lt; 11 µM ( &lt; 80 mg/dL ) Baseline force expiratory volume one second ( FEV1 ) &gt; = 50 % predict , measure 30 minute shortacting inhaled bronchodilator Baseline arterial oxygen percent saturation ( SaO2 ) within normal limit individual study site For subject receive inhaled corticosteroid , β2 agonist ( eg , albuterol via meter dose inhaler [ MDI ] ) anticholinergic bronchodilator ( eg , ipratropium bromide ) , treatment stable dose least 14 day prior randomization If female childbearing potential , negative urine pregnancy test within 3 day prior randomization agreement employ adequate birth control measure No clinically significant abnormality detect 12lead electrocardiogram ( ECG ) perform 7 day prior randomization Baseline laboratory result , obtain 7 day prior randomization , meet follow criterion : Serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; = 2 time upper limit normal range ( ULN ) Serum total bilirubin &lt; = 2 time ULN &lt; 2+ proteinuria urine dipstick Serum creatinine &lt; = 1.5 time ULN Absolute neutrophil count &gt; = 1500 cells/mm3 Hemoglobin &gt; = 10.0 g/dL Platelet count &gt; = 100,000/mm3 Signed inform consent Clinically significant pulmonary impairment , emphysema and/or chronic bronchitis Clinically significant cardiac , hemostatic , neurologic impairment , significant medical condition , opinion investigator , would affect subject safety compliance Psychiatric cognitive disturbance illness , recreational drug/alcohol use , opinion investigator , would affect subject safety compliance Acute exacerbation emphysema ( defined Section 8.5.10 ) within 28 day prior randomization Pregnancy lactation Known history allergy yeast product Medical history precluding use epinephrine rescue medication treatment anaphylaxis Use antihistamine within 7 day prior randomization Use oral steroid , betablockers , tricyclic antidepressant within 28 day prior randomization Use another investigational drug investigational device within 28 day prior randomization Any upper low respiratory infection within 28 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>